---
document_datetime: 2024-08-14 17:13:42
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/leflunomide-zentiva-previously-leflunomide-winthrop-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: leflunomide-zentiva-previously-leflunomide-winthrop-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.6448672
conversion_datetime: 2025-12-24 09:06:39.971398
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Leflunomide Zentiva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|----------------------|----------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1837/ 202309   | Periodic Safety Update EU Single assessment - leflunomide                                    | 30/05/2024                          | 24/07/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1837/202309. |
| IB/0041/G            | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a | 21/06/2024                          |                                             | Annex II and PL                  |                                                                                                                                           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| manufacturing operation(s) release, batch control, primary packaging, for non-sterile B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.b - Replacement manufacturing site for the site B.II.b.2.c.2 - Change to importer, arrangements and quality Including batch control/testing B.II.b.2.c.2 - Change to importer, arrangements and quality Including batch control/testing B.II.b.4.a - Change in the size ranges) of the finished compared to the originally B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.b.3.z - Change in the the finished or intermediate B.II.b.5.z - Change to in-process applied during the manufacture product - Other variation B.II.d.2.a - Change in test product - Minor changes procedure B.II.d.2.a - Change in test product - Minor changes   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0040/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 18/04/2024 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |                                  |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IB/0038            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                      | 09/01/2024 | n/a        |                                  |                                   |
| IB/0037            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                       | 13/05/2022 | 05/05/2023 | SmPC, Labelling and PL           |                                   |
| IAIN/0036          | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                         | 20/07/2021 | 18/03/2022 | Annex II and PL                  |                                   |
| PSUSA/1837/ 202009 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                          | 06/05/2021 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0035            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                       | 08/03/2021 | 18/03/2022 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| T/0032             | Transfer of Marketing Authorisation                                                                                                                                                                                 | 21/09/2018   | 16/10/2018   | SmPC, Labelling and PL           |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------|
| IAIN/0031          | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                     | 24/08/2018   | 16/10/2018   | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/1837/ 201709 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                           | 12/04/2018   | n/a          |                                  | PRAC Recommendation - maintenance |
| N/0030             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                    | 09/04/2018   | 25/06/2018   | Labelling and PL                 |                                   |
| IG/0823            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                      | 14/07/2017   | 25/06/2018   | SmPC and PL                      |                                   |
| PSUSA/1837/ 201609 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                           | 06/04/2017   | n/a          |                                  | PRAC Recommendation - maintenance |
| IA/0026            | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 03/06/2016   | n/a          |                                  |                                   |
| N/0025             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                    | 19/05/2016   | 14/10/2016   | PL                               |                                   |
| PSUSA/1837/ 201509 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                           | 14/04/2016   | n/a          |                                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IG/0635            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                        | 14/12/2015   | 14/10/2016   | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0816/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 22/10/2015   | 14/10/2016   | SmPC, Annex II and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/1837/ 201409 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                                             | 10/04/2015   | n/a          |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0018             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                               | 25/09/2014   | 19/11/2014   | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of leflunomide winthrop continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Leflunomide winthrop continues to be favourable in the treatment of active rheumatoid arthritis as a \"disease-modifying antirheumatic drug\" (DMARD), and active psoriatic arthritis. The CHMP recommended the renewal of the Marketing Authorisation with unlimited validity. |
| WS/0560/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                               | 25/09/2014   | 19/11/2014   | SmPC and PL                      | With the development of teriflunomide, the main active metabolite of leflumonide, as a drug for the treatment of multiple sclerosis, several interaction studies were performed according to current standards. This variation                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| This worksharing includes 9 type II variations per product grouped as follows: -Type II variation, C.I.4 : Update of sections 4.3 and 4.4 of the SmPC contraindicating and including a warning on teriflunamide the active metabolite of leflunomide; -2 Type II variations, C.I.4 : Update of section 4.5 of the SmPC for leflunomide related to the study reports HWA486/1032/001 (interaction cimetidine) and -HWA486/2F0.1 (interaction with methotrexate); - 6 Type II variations, C.I.4 : Update of section 4.5 of the SmPC for teriflunomide related to the following Study reports INT11697-INT11720-INT12503- INT12500-INT10564-INT6040. In addition and following CHMP request section 4.4 of the SmPC was updated to include a warning for patients to be evaluated for tuberculosis before starting treatment with leflunomide. The PL was revised to reflect the above warnings and interactions. Furthermore, the MAH took the opportunity of this worksharing to reflect the interaction studies in the RMP and to include DRESS syndrome in the RMP as requested by PRAC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | hamonised the results of the interaction studies of the main metabolite with the parent drug leflumonide. Caution and intensified monitoring is recommended for combined use of leflunomide and a broad range of products since the plasma levels may be increased by the concurrent use of leflumonide. The benefit/risk balance of leflumonide remains positive, considering that interactions could be controlled by dose adjustments. Co administration of teriflunomide with leflunomide is not recommended, as leflunomide is the parent compound of teriflunomide.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |             |                                                                                                                                                                                                                                                                                     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0454 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17/07/2014 | n/a        |             |                                                                                                                                                                                                                                                                                     |
| WS/0526 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/05/2014 | 19/11/2014 | SmPC and PL | 14 cases of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) have been retrieved. 10 cases are reports from literature articles and 4 are spontaneous. Of the 14 cases, 7 provide insufficient or inconclusive information. The remaining 7 spontaneous and literature |

<div style=\"page-break-after: always\"></div>

|                    | to add a warning and update the safety information on DRESS (drug reaction with eosinophilia and systemic symptoms). The section 2 and 4 of the Package Leaflet were proposed to be updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives for Finland, Malta, Sweden and United Kingdom in the Package Leaflet. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   |            |            |             | cases of DRESS have (strong) suggestive evidence and strong temporal association with leflunomide (2 'definite' and 5 'possible' cases according to the RegiSCAR criteria). The product information has therefore been updated to include that cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported in patients treated with leflunomide. The MAHs of generic products containing leflunomide will update their product information in line with that of the reference product.   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1837/ 201309 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                                                                                                                                                             | 10/04/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0016            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                          | 20/02/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0354            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                        | 05/11/2013 | 19/11/2014 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0314            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                        | 08/07/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0271            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC to add cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis and warn physicians about these                                                                                                                                                              | 15/11/2012 | 20/12/2012 | SmPC and PL | Based on published clinical trial data and single case reports in the scientific literature, a possible causal association of leflunomide treatment with worsening of underlying psoriasis and pustular psoriasis is strongly suggested by two cases identified from the company global pharmacovigilance database reporting positive rechallenge after reintroduction of leflunomide. No similar published                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| skin reactions. The PL is being updated accordingly. Furthermore, the list of local representatives in section 6 of the PL is being updated. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  | history.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------|
| IA/0011/G | This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                         | 19/03/2012 | n/a        |                                  |            |
| II/0006   | Update of section 4.4 of the SmPC to strengthen the warning regarding peripheral neuropathy. The PIL is updated accordingly. Furthermore, changes relating to the implementation of the latest QRD template are being proposed. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                         | 16/02/2012 | 19/03/2012 | SmPC, Annex II, Labelling and PL |            |
| IG/0147/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD | 29/02/2012 | n/a        |                                  |            |

<div style=\"page-break-after: always\"></div>

|         | system as described in the DDPS - Deletion of topics covered by written procedure(s) describing pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005 | Update of section 4.4 of the SmPC regarding the risk of leflunomide use in combination with biologicals following the CHMP assessment of the COLEBI study. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH             | 22/09/2011 | 27/10/2011 | SmPC | The COLEBI study is a retrospective observational study comparing RA patients who were treated with a combination of leflunomide + TNF-inhibitor with those who were treated with a combination of MTX + TNF-inhibitor. Following the assessment of the results of the COLEBI study, which have been submitted as a follow-up measure, the MAH was asked to update the warning section of the SmPC to with regard to the combined use of leflunomide and TNF-Inhibitors. Furthermore, the warning section has been updated regarding the risk of tuberculosis and the need for appropriate testing.                                                                                            |
| II/0003 | Update of sections 4.2 and 5.1 of the SmPC to reflect the outcome of the clinical study R01143 (LEADER) regarding the use of a loading dose, as requested by the CHMP. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 23/06/2011 | 27/07/2011 | SmPC | The MAH has conducted a post-marketing study (R01143, LEADER) in which two initial dosing regimen were used, 121 DMARD-naive patients with early RA were randomized to receive either the 20 mg or 100 mg starting dose in a double-blind, double-dummy fashion, followed by an open- label maintenance period of 3 months during which 20mg/d where administered. The ACR20 response rate at 90 days (primary endpoint) was statistically significantly higher in the flat-dose group compared to the loading dose group. There were, however, no significant differences for any of the secondary efficacy parameters, such as ACR50 or DAS28 response and, also considered the small sample |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                       | size, superiority of flat dosing regimen above the 100 mg loading dose cannot be concluded. However, there appears to be no loss of clinical response in the flat dose regimen as compared to the loading dose regimen. The incidence of gastrointestinal AEs and of elevated liver enzymes reported as adverse events tended to be higher during the earlier phases of treatment in patients receiving the loading dose of 100 mg leflunomide. Overall, the safety data obtained were consistent with the known safety profile of leflunomide.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0091 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/07/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0004 | Update of 4.4 of the SmPC to amend the warning for interstitial lung disease (ILD) as requested by the CHMP. The PIL was revised accordingly. In addition the description of the risk of teratogenicity in the PIL was aligned with the educational material agreed in August 2010. Further updates concerns the Annex IIB regarding DDPS / RMP version and the implementation of the latest QRD template. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 17/03/2011 | 18/04/2011 | SmPC, Annex II and PL | Following a CHMP request, the MAH conduct a search of recent relevant literature on interstitial lung disease (IDL) in association with leflunomide treatment as a follow-up measure. Following the assessment of the information provided by the MAH, an update of section 4.4 of the SmPC was requested to highlight the increased risk in case of pre- existing IDL. Furthermore, the MAH has aligned the information on serious birth defects in the package leaflet with the Patient Sheet (educational material) of the EU- RMP.            |

<div style=\"page-break-after: always\"></div>

| IB/0002   | To update section 4.4 of the SmPC with information on PML. Minor editorial changes have also been made to section 2 of the SmPC, the labelling and the package leaflet. The MAH has also taken the opportunity to correct the contact details of the Slovak Republic local representative. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                            | 25/05/2010   | n/a   | SmPC and PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------|
| IG/0004/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 06/05/2010   | n/a   | Annex II      |